Kymera Therapeutics (KYMR) Cash from Investing Activities (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Cash from Investing Activities for 8 consecutive years, with -$142.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 393.82% year-over-year to -$142.8 million; the TTM figure through Mar 2026 stood at -$712.5 million (down 2766.69% YoY), while the FY2025 annual figure was -$521.1 million, down 28.95% from the prior year.
• Cash from Investing Activities climbed to -$142.8 million in Q1 2026 per KYMR's latest filing, from -$394.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $81.8 million in Q2 2022 and bottomed at -$394.4 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$53.4 million across 5 years, with a median of $19.0 million in 2023.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities sank 1444.81% — and 2025, when it surged 283.72%.
• Kymera Therapeutics' Cash from Investing Activities stood at -$49.7 million in 2022, then soared by 138.16% to $19.0 million in 2023, then jumped by 261.8% to $68.6 million in 2024, then sank by 675.19% to -$394.4 million in 2025, then surged by 63.78% to -$142.8 million in 2026.
• Business Quant data shows KYMR's Cash from Investing Activities at -$142.8 million in Q1 2026, -$394.4 million in Q4 2025, and -$235.3 million in Q3 2025.